REFERENCES
- Brade WP, Herdrich K, Varini M. Ifosfamide pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12: 1–47.
- Granvil CP, Ducharme J, Leyland-Jones B, Trudeau MW, Wainer I. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemother Pharmacol 1996; 37: 451–456.
- Kaijser GP, Keizer HJ, Beijnen JH, BuIt A, Underberg WJM. Pharmacokinetics of ifosfamide, 2- and 3-dechloro-ethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res 1996; 16: 3247-3258.
- Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
- Walker D, Flinois J-P, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994; 47: 1157-1161.
- Kurowski V, Cerny T, Kupfer A, Wagner T. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Clin Oncol 1991; 117 ( Suppl IV): 148-153.
- Leblanc GA, Waxman DJ. Mechanism of cyclophos-phamide action on hepatic P-450 expression. Cancer Res 1990; 50: 5720-5726.
- Sladek N. Metabolism of oxazaphosphorine. Pharmacol Ther 1988; 37: 301–355.
- Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophos-phamide. Biochem Pharmacol 1973; 23: 115–129.
- Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 1996; 38: 147–154.
- Lind MJ, Roberts HL, Thatcher N, Idle JR. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 1990; 26: 105–111.
- Wainer IW, Ducharme J, Granvil CP, Trudeau M, Leyland-Jones B. Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 1994; 383: 982–983.
- Lewis LD, Fitzgerald DL, Mohan P, Thatcher N, Harper PG, Rogers HJ. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 1991; 31: 77–82.
- Kaijser GP, Korst JH, Beijnen JH, Underberg WJM. The analysis of ifosfamide and its metabolites. Anticancer Res 1993; 13: 1311–1324.
- Burton LC, James CA. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatogr 1988; 431: 450–454.
- Margison JM, Wilkinson PM, Cerny T, Thatcher N. A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr 1986; 1: 101–103.
- Masurel D, Wainer IW. Analytical and preparative high performance liquid chromatographic separation of the enantiomers of ifosfamide, cyclofosfamide and trofosfamide and their determination in plasma. J Chromatogr 1989; 490: 133–143.